This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

27/100

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Alzheimer disease (AD) is the neurodegenerative condition that occurs in the elderly population above 65 years old and is the major cause of dementia. AD is characterized by memory loss, behavioural changes, and cognitive dysfunction. AD has complex pathophysiology with different mechanisms that include the accumulation of amyloid beta plaques, the formation of neurofibrillary tangles due to the hyper phosphorylation of tau, oxidative stress, and neuroinflammation, dysfunction of the mitochondria, cholinergic insufficiency, and excitotoxcity. Various risk factors include the Apolipoprotein E (APOE) ε4, unhealthy life styles, and environments. The FDA-available drugs include the ones that inhibit the cholinesterase enzyme (donepezil, rivastigmine, and galantamine) or the ones that inhibit the NMDA receptor (memantine), which can decrease the effect but not prevent the disease. Emerging approaches include anti-amyloid antibodies, BACE1, gamma-secretases, anti-tau therapies, stem cell, and gene therapies. Plant medicines have been used for centuries; currently they have been used to cure or prevent AD. The plant has neuroprotective, antioxidant, anti-inflammatory, anti-amyloid, and anti-tau effects. Some phytoconstituents have shown the positive effect on the disease-related pathways: Curcumin, resveratrol, backsides, and withanolides. The current review shows the multifactorial aspect of Alzheimer disease, the summary of the current and new therapeutic methods, and the potential of medicinal plants and their phytoconstituents as safer and efficient alternatives to the current treatment of Alzheimer disease

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kumar, I., Rani, D., & Pathania, K. (2026). Alzheimer’s disease: Pathophysiology, current and emerging therapeutic approaches for Alzheimer’s disease. Current Trends in Pharmacy and Pharmaceutical Chemistry. https://doi.org/10.18231/j.ctppc.39626.1776405949

Vancouver

Kumar I, Rani D, Pathania K. Alzheimer’s disease: Pathophysiology, current and emerging therapeutic approaches for Alzheimer’s disease. Current Trends in Pharmacy and Pharmaceutical Chemistry. 2026. doi:10.18231/j.ctppc.39626.1776405949.

BibTeX

@article{kumar2026-411be862,
  author  = {Kumar, Itesh and Rani, Deepika and Pathania, Komal},
  title   = {{Alzheimer’s disease: Pathophysiology, current and emerging therapeutic approaches for Alzheimer’s disease}},
  journal = {Current Trends in Pharmacy and Pharmaceutical Chemistry},
  year    = {2026},
  doi     = {10.18231/j.ctppc.39626.1776405949},
  url     = {https://doi.org/10.18231/j.ctppc.39626.1776405949}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Emerging approaches include anti-amyloid antibodies, BACE1, gamma-secretases, anti-tau therapies, stem cell, and gene therapies.
Plant medicines have been used for centuries; currently they have been used to cure or prevent AD.
The plant has neuroprotective, antioxidant, anti-inflammatory, anti-amyloid, and anti-tau effects.
Some phytoconstituents have shown the positive effect on the disease-related pathways: Curcumin, resveratrol, backsides, and withanolides.
The current review shows the multifactorial aspect of Alzheimer disease, the summary of the current and new therapeutic methods, and the potential of medicinal plants and their phytoconstituents as safer and efficient alternatives to the current treatment of Alzheimer disease

Why it matters

This review states that currently FDA-available drugs for Alzheimer's disease can decrease symptoms but not prevent the disease. It lists emerging approaches such as anti-amyloid antibodies, anti-tau therapies, stem cell and gene therapies, and plant compounds, but presents no confirmed cure or prevention.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 27/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Current Trends in Pharmacy and Pharmaceutical Chemistry)
Journal's citation record	0 / 4	Current Trends in Pharmacy and Pharmaceutical Chemistry: journal h-index 7 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Komal Pathania holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	Baddi University of Emerging Sciences and Technologies: institution h-index 40 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	26 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100.
Total	27 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Treatments

Also in Treatments

166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →